Pamiparib is a potent and selective PARP inhibitor with unique potential for the treatment of brain tumor

Pamiparib, an investigational Poly (ADP-ribose) polymerase (PARP) inhibitor in clinical development, demonstrates excellent selectivity for both PARP1 and PARP2, and superb anti-proliferation activities in tumor cell lines with BRCA1/2 mutations or HR pathway deficiency (HRD). Pamiparib has good bio...

Full description

Bibliographic Details

Published in:	Neoplasia (New York, N.Y.) Vol. 22; no. 9; pp. 431 - 440
Main Authors:	Xiong, Yao, Guo, Yin, Liu, Ye, Wang, Hexiang, Gong, Wenfeng, Liu, Yong, Wang, Xing, Gao, Yajuan, Yu, Fenglong, Su, Dan, Wang, Fan, Zhu, Yutong, Zhao, Yuan, Wu, Yiyuan, Qin, Zhen, Sun, Xuebing, Ren, Bo, Jiang, Bin, Jin, Wei, Shen, Zhirong, Tang, Zhiyu, Song, Xiaomin, Wang, Lai, Liu, Xuesong, Zhou, Changyou, Jiang, Beibei
Format:	Journal Article
Language:	English
Published:	United States Elsevier Inc 01.09.2020 Neoplasia Press Elsevier
Subjects:	Brain penetration Original article Pamiparib PARP TMZ TMZ PARP Brain penetration Pamiparib
ISSN:	1476-5586, 1522-8002, 1476-5586
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!